GRAL News

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Form 8-K

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology

Mercy Joins Clinical Study for Blood Test That Screens for Multiple Types of Cancers

MCESC Deepens Countywide Efforts to Re-Engage Students and Strengthen Pathways to Success

GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)